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Abstract 
The objective of the present work was to develop a stability-indicating RP-HPLC 
method for duloxetine hydrochloride (DUL) in the presence of its degradation 
products generated from forced decomposition studies. The drug substance 
was found to be susceptible to stress conditions of acid hydrolysis. The drug 
was found to be stable to dry heat, photodegradation, oxidation and basic 
condition attempted. Successful separation of the drug from the degradation 
products formed under acidic stress conditions was achieved on a Hypersil 
C-18 column (250 mm X 4.6 mm id, 5μm particle size) using acetonitrile: 0.01 M 
potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric 
acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification 
was achieved with photodiode array detection at 229 nm over the concentration 
range 1–25 μg/ml with range of recovery 99.8–101.3 % for DUL by the 
RP-HPLC method. Statistical analysis proved the method to be repeatable, 
specific, and accurate for estimation of DUL. It can be used as a stability-
indicating method due to its effective separation of the drug from its degradation 
products, 
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Introduction 
Duloxetine HCl (DUL) – (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-
1-amine hydrochloride [1] – has an empirical formula of C18H19NOS⋅HCl and a molecular 
weight of 333.38 g/moL (Figure 1). It is a potent inhibitor of serotonin and norepinephrine 
reuptake and thus it is used for major depressive disorders [2–4]. Furthermore, it provides 
evidence of an effect on pain in the case of urinary incontinence [5, 6] independent of its 
effect on depression. Therefore, DUL is an alternative to current therapeutic options in the 
treatment of the different symptoms of depression [7].  
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Fig. 1.   Structure of DUL 
A literature survey indicated few methods for the determination of DUL and its key 
intermediate, desmethyl-duloxetine, in human serum by HPLC [8, 9]. Reports were found 
regarding the characterization of phenolic impurities in DUL samples by MS, NMR 
spectrometry, and X-ray analysis [10] and of impurities formed by interaction of DUL with 
various enteric polymers [11]. A simple UV spectrophotometric method for the estimation 
of DUL in a formulation was reported [12]. An HPLC method separated DUL and 
structurally related impurities using a combination of computer-based solvent strength 
optimization and solvent selectivity mixture design [13]. An HPTLC method separated DUL 
in bulk and in tablet dosage form [14]. A capillary electrophoresis with laser-induced 
fluorescence detection method (Musenga et al, 2009) also reported for estimation of DUL 
in human plasma [15]. 
During our literature survey, one article related to the stability-indicating HPLC 
determination of DUL was found but it’s less sensitive as compare to LOD and LOQ and 
for linearity range is not wide [16]. International Conference on Harmonization (ICH) 
guidelines requires stress testing to be carried out to elucidate the inherent stability 
characteristics of the active drug substance [17]. The aim of the present work was to 
develop an accurate, selective, precise, robust, and stability-indicating RP-HPLC method 
for the determination of DUL in the presence of its degradation products and related 
impurities in tablets. The proposed method was validated according to ICH guidelines 
[18,  19] and its updated international convention ICH guideline on analytical method 
validation [20]. 
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Result and Discussion 
Optimization of the chromatographic conditions: 
HPLC Method 
Several mobile phases were tried to resolve DUL but the resolution was not satisfactory. 
So modification was made in the above mobile phase. Finally the system containing 
acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with 
orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min was 
found to be satisfactory and gave well resolved peak for DUL. The retention time for DUL 
was 5.84 min. For the selection of detection wavelength, the spectrum of 10 ppm DUL 
revealed that, at 229 nm the drug possesses significant absorbance. So considering above 
fact, 229 nm was selected as a detection wavelength for estimation of DUL using HPLC. 
Complete resolution of the peaks with clear baseline separation was obtained (Figure 2). 
The system suitability test parameters are shown in Table 1. 
 
Fig. 2.   HPLC chromatogram of Duloxetine hydrochloride (RT 5.84 min) on C18 hypersil 
column using 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted 
with orthophosphoric acid) (50:50, v/v) as the mobile phase  
Tab. 1.   System suitability test parameters for Duloxetine hydrochloride at the proposed 
HPLC method 
Parameter Duloxetine  HCl 
Retention times (RT) 5.84  Min 
HPLC Plate Count  6394 
Tailing factor  1.27 
Base width (sec)  20.98 
 
Validation of the Proposed Methods 
The developed method was validated, as described below, for various parameters like 
linearity and range, accuracy, precision, ruggedness, system suitability, specificity, LOQ, 
and LOD. 
Linearity and Range 
Linearity of the method was evaluated at six concentration levels by diluting the standard 
stock solution to give solutions in the range of 1.0–25µg/ml. The calibration curve for DUL 860  U. K. Chhalotiya et al.:  
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was prepared by plotting area v/s concentration. Calibration data for DUL was shown in 
Table 2. The linearity plot of DUL was found to be linear with the linear equation  
y = 80042 x – 72864  
and correlation coefficient 0.998 for DUL. Linearity was observed in the expected 
concentration range, demonstrating suitability of the method for analysis. This indicates 
that the method is linear in the specified range for the analysis of DUL in dosage form.  
Tab. 2.   Regression analysis of calibration graphs for Duloxetine hydrochloride by 
proposed HPLC method 
Parameter Duloxetine  hydrochloride 
Linearity (µg/ml)  1–25 
Correlation co –efficient (r)  0.998 
Slope of Regression(S)  80042 
Intercept of Regression  72864 
Standard deviation of slope  23.1 
Standard deviation of intercept  63.53 
 
Accuracy 
The recovery experiments were carried out by the standard addition method. The method 
was found to be accurate with % recovery 99.78%–101.21% and has found with 
acceptable %RSD of not more than 2% at each level. The recoveries obtained by the RP-
HPLC method for DUL are shown in Table 3. 
Tab. 3.   Data derived from accuracy of Duloxetine hydrochloride the proposed HPLC 
method 
Amount of 
Sample 
(µg/ml) 
Sets 
Amount drug 
of spiked  
(µg/ml) 
Area(n=3)
Average 
amount 
recovered
(µg/ml) 
% 
Recovery 
Mean % 
Recovery 
%  
RSD
a
1 0  244245.3 99.04 
2 0  246259.7 99.67  4 
3 0  248358.1
3.99 
100.32 
 99.78   0.84
1 2  410442.1 100.9 
2 2  407248.4 99.96  4 
3 2  411122.8
6.02 
101.17 
100.68   0.51
1 4  569276.0 100.56 
2 4  571411.2 101.2  4 
3 4  568677.9
8.03 
100.38 
100.71   0.25
1 6  732162.2 101.44 
2 6  731173.0 101.13  4 
3 6  730944.2
10.05 
101.06 
101.21 0.089
a RSD = Relative standard deviation. 
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Precision 
Instrument precision was determined by performing repeatability test and the %RSD 
values for DUL were found to be 0.4. The intra-day and inter-day precision studies were 
carried out to study the precision of the developed method. For intra day study the % RSD 
value were found to be 0.12 – 0.36 and for interday study %RSD value were found to be 
0.11 – 0.56 (Table 4). The low RSD values indicate that the method is precise. 
Tab. 4.  Summary of validation parameters for Duloxetine hydrochloride the proposed 
HPLC method 
Parameters Duloxetine  hydrochloride 
LOD (µg/ml)
a 0.0257 
LOQ (µg/ml)
b n=5  0.0779 
Accuracy, %  99.8–101.3 
Repeatability, (% RSD, n = 6)  0.0050–0.303 
Precision (% RSD) 
Interday (n = 3) 
Intraday (n = 3) 
 
0.11–0.56 
0.12–0.36 
a LOD = Limit of detection; 
b LOQ = Limit of quantitation. 
 
Ruggedness 
Ruggedness test was determined between two different days, analysts and instruments. 
The value of RSD was to be found 0.9 which is within acceptance criteria of below 2.0% 
showed ruggedness of developed HPLC method. 
Specificity (Placebo interference) 
There is no interference of mobile phase, solvent and placebo with the analyte peak and 
also the peak purity of analyte peak which indicate that the method is specific for the 
analysis of DUL in their dosage form.  
Robustness 
The method was found to be robust, as small but deliberate changes in the method 
parameters have no detrimental effect on the method performance as shown in Table 5. 
The low value of relative standard deviation was indicating that the method was robust. 
Tab. 5.   Data derived from robustness of Duloxetine hydrochloride the proposed HPLC 
method 
Parameters Normal  condition  Change in condition  Change in % RSD 
0.9 ml/min  0.11  Flow Rate  1.0 ml/min  1.1 ml/min  0.25 
4.9 0.083  pH 5.4  5.9 0.11 
45:55 0.079  Mobile phase ratio  50:50  55:45 0.17 862  U. K. Chhalotiya et al.:  
Sci Pharm. 2010; 78: 857–868. 
 
Stability of standard and sample solutions  
Stability of standard and sample solution of DUL was evaluated at room temperature for 
48 hr. The relative standard deviation was found below 2.0%. It showed that both standard 
and sample solution were stable up to 48 hr at room temperature. 
LOD and LOQ 
These data show that the method is sensitive for the determination of DUL. The LOD and 
LOQ were measured by using an equation and were found to be 0.026 and 0.078 µg/ml, 
respectively. 
Analysis o f a Formulation 
The proposed method was applied for the determination of DUL in tablets of Duloxetine 
HCl. The results of these assays was 99.75% (RSD = 0.84%) of the label claim for the 
formulation. The results of the assay indicated that the method is selective for the assay of 
DUL without interference from excipients used in the tablets (Table 6). 
Tab. 6.   Assay results for Duloxetine hydrochloride in marketed tablet dosage form by 
proposed HPLC method 
Tablet  Concentration  
(µg/ml) 
Amount recovered 
(µg/ml)  Duloxetine HCl ± SD
a (n =3), % 
A  4  3.99  99.75 ± 2.056 
a SD = Standard deviation 
 
 
Fig. 3.   Chromatogram of acid (0.1M HCl) treated DUL at room temperature for 24 hr.  
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Forced degradation study was carried out by subjecting the drug to acid and alkali 
hydrolysis, chemical oxidation, dry heat degradation and photolytic (sun light) conditions. 
The chromatograms of acid degraded sample showed complete degradation product 
peaks at retention time (Rt) 2.49, 3.04, 3.77 and 7.21 min for DUL. The peaks of the 
degradation products were well resolved which is shown in (Figure 3). The DUL was found 
to be stable to rest of the conditions like oxidative stress degradation, dry heat degradation 
and alkali hydrolysis.  
The degradation study thereby indicated that DUL was stable to chemical oxidation study, 
dry heat and alkali hydrolysis while it was highly susceptible to acid hydrolysis (Table 7).  
Tab. 7.   Forced degradation study for Duloxetine HCl the proposed HPLC method 
Condition Time  (h)  % Recovery 
DUL 
Retention time of 
degradation products 
Base 0.1 N NaOH  24  99.9  – 
Acid 0.1 N HCl  24  2.86  2.49, 3.04, 3.77 and 7.21 
3% hydrogen peroxide  24  100.7  – 
Dry heat
a 24  99.7  – 
Sunlight 24  99.3  – 
a Samples were heated at 80 
o for specified period of time. 
 
Conclusions 
A validated stability-indicating HPLC analytical method has been developed for the 
determination of DUL in bulk and in tablet dosage form. The results of stress testing 
undertaken according to the ICH guidelines revealed that the method is selective and 
stability-indicating. The proposed method is simple, accurate, precise, and specific, and it 
has the ability to separate the drug from degradation products and excipients found in the 
dosage form. The method is suitable for the routine analysis of DUL in tablets. In addition, 
the HPLC procedure can be applied to the analysis of samples obtained during 
accelerated stability experiments to predict expiration dates of pharmaceuticals. 
Experimental 
Apparatus 
A Series 200 HPLC system (PerkinElmer, Shelton, CT) equipped with a Series 200 diode 
array detector, Series 200 quaternary gradient pump, Series 200 column oven, manual 
injector rheodyne valve) with 20 µL fixed loop, Turbochrom navigator software (Version 
6.1.1.0.0:K20), and Hypersil C18 column (150mm× 4.6mmid, 5 µm particle size) was used.  
Reagents and Materials 
o  Pure samples: Analytically pure powder Duloxetine hydrochloride was procured as 
gratis samples from Sun Pharmaceuticals Limited, Gujarat, India.  
o  Chemicals and reagents: HPLC grade water, acetonitrile and orthophosphoric acid 
was purchased from E. Merck (Mumbai, India).  864  U. K. Chhalotiya et al.:  
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o  Market samples: Tablets containing Duloxetine HCl (20mg) of brand Torrent 
Pharmaceuticals Ltd., Ahmedabad (Gujarat, India) were purchased from the local market. 
Chromatographic Conditions 
The Hypersil C18 column (18) was used at ambient temperature. The mobile phase 
consisted of acetonitrile-buffer (0.01 M Potassium dihydrogen phosphate, pH 5.4 adjusted 
with ortho-phosphoric acid) (50:50, v/v) and the flow rate was maintained at 1 ml/min. The 
mobile phase was passed through nylon 0.45 µm–47 mm membrane filter and degassed 
before use. The elution was monitored with UV detector at 229  nm, and the injection 
volume was 20 µL. 
HPLC method depends upon the nature of the sample (ionic or ionizable or neutral 
molecule), its molecular weight and solubility. UPLC was selected for the initial separation 
because of its simplicity and suitability. To optimize the chromatographic conditions the 
effect of chromatographic variables such as mobile phase, pH, flow rate and solvent ratio 
were studied. The resulting chromatograms were recorded and the chromatographic 
parameters such as capacity factor, asymmetric factor, and resolution and column 
efficiency were calculated. The condition that gave the best resolution, symmetry and 
capacity factor was selected for estimation. 
Preparation of DUL Standard Stock Solutions (100µg/ml) 
Accurately weighed 25 mg of DUL transferred to a 25ml volumetric flask and dissolved and 
diluted to the mark with methanol to obtain a standard solution of 1000 μg/ml. This solution 
(1 ml) was further diluted to 10 ml with mobile phase to obtain a working standard stock 
solution of 100μg/ml for the RP- HPLC method. 
Preparation of Sample Solutions 
Twenty tablets were weighed and finely powdered. A mass equivalent to 20 mg of DUL 
was weighed and transferred in a 100 ml volumetric flask, mixed with methanol (60 ml), 
and sonicated for 20 min. The solution was filtered through Whatman filter paper No. 41, 
and the residue was washed thoroughly with methanol. The filtrate and washings were 
combined in a 100 ml volumetric flask and diluted to the mark with methanol. An aliquot of 
this solution (0.2 ml) was further diluted to 10 ml with methanol to obtain a solution 
containing 4 µg/ml of DUL and subjected to RP-HPLC analysis. 
Method Validation 
Linearity and range 
Calibration curves were constructed by plotting peak areas versus concentrations of DUL, 
and the regression equations were calculated. The calibration curves were plotted over the 
concentration range 1–25 µg/ml. Accurately measured standard working solutions of DUL 
(0.1, 0.2, 0.4, 0.8, 1.0, 2.0, and 2.5ml) were transferred to a series of 10 ml volumetric 
flasks and diluted to the mark with mobile phase. Aliquots (20 µL) of each solution were 
injected under the operating chromatographic conditions described above. 
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The accuracy of the method was determined by calculating recoveries of DUL by the 
standard addition method. Known amounts of standard solutions of DUL (50, 100, and 
150%) were added to prequantified sample solutions of tablets. The amounts of DUL were 
determined by applying these values to the regression equation of the calibration curve. 
Method precision (repeatability) 
The precision of the instruments was checked by repeatedly injecting (n = 6) solutions of 
DUL (5 µg/ml) for the RP-HPLC method. 
Intermediate precision 
Precision was evaluated in terms of intraday and interday precision. The intraday precision 
was investigated using different concentrations (1, 5, 25 µg/ml) of standard solutions and 
sample solutions. The intraday and interday precisions of the proposed methods were 
determined by estimating the corresponding responses three times on the same day and 
on three different days over a period of 1 week for different concentrations of DUL 
standard and sample, respectively. The results were reported in terms of RSD. 
Robustness 
To determine the robustness of the developed method, experimental conditions were 
deliberately altered and the effect on resolution was recorded. There was no detrimental 
effect on the method performance as shown. Low value of relative standard deviation was 
indicating that the method was robust. 
LOD and LOQ 
The LOD was determined by the analysis of samples with known concentrations of analyte 
and by establishing through visual evaluation the minimum level at which the analyte could 
be reliably detected. The LOQ was determined by the analysis of samples with known 
concentrations of analyte and by establishing the minimum level at which the analyte could 
be quantified with acceptable accuracy and precision. 
Specificity 
To assess the method specificity, tablet powder without DUL was prepared with the same 
excipients as those of in the commercial formulation. For RP-HPLC, the solution was 
prepared using the same procedure as for the analytical sample. Moreover, to evaluate the 
influence of the putative degradation products on the resolution of DUL, a standard stock 
solution was prepared as reported above, except for the addition of DUL at a 1 μg/ml 
concentration. HPLC analysis was performed after dilution, as reported for the working 
standard solution. Resolution factors were calculated with the LC solution software. The 
specificity of the method was established through study of resolution factors of the drug 
peak from the nearest resolved peak, and among all other peaks. Selectivity was 
confirmed through peak purity studies using the UV detector. 
System suitability 
A system suitability test was an integral part of the method development to verify that the 
system is adequate for the analysis of DUL to be performed. The suitability of the 
chromatographic system was demonstrated by comparing the obtained parameter values 866  U. K. Chhalotiya et al.:  
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with the acceptance criteria of the U.S. Food and Drug Administration, Center for Drug 
Evaluation and Research guidance document (U.S. Food and Drug Administration, 1994). 
A system suitability test of the chromatography system was performed before each 
validation run. Six replicate injections of a system suitability/calibration standard and one 
injection of a check standard were made. Area, retention time (RT), tailing factor, 
asymmetry factor, and theoretical plates for the six suitability injections were determined. 
Stability of standard and sample solutions  
Stability of standard and sample solution of DUL was evaluated at room 
temperature for 48 hr. The relative standard deviation was found below 2.0%. It 
showed that both standard and sample solution were stable up to 48 hr at room 
temperature. 
Determination of DUL in Tablets  
Tablets of DUL were purchased from a local market. The responses of tablet solutions 
measured with the UV detector showed a wavelength maximum at 229 nm for the RP-
HPLC method. The amounts of DUL present in sample solution were determined by fitting 
the responses into the regression equation for DUL. 
Forced Degradation of DUL 
DUL is practically insoluble in water but very soluble in methanol; therefore, methanol was 
used as the solvent in all studies. After forced degradation studies all the resultant 
solutions were diluted using methanol to obtain final concentration of 10 µg/ml of DUL.  
(a) Oxidation: Solutions of DUL (10 µg/ml) for oxidation studies were prepared using 3% 
H2O2 in methanol, and the resultant solutions were stand for 24 hr to facilitate oxidation of 
the DUL. 
(b) Acid degradation: Solutions of DUL (10  µg/ml) for acid degradation studies were 
prepared using 0.1 M HCl in methanol and the resultant solutions were stand for 24 hr. 
(c) Alkali degradation: Solutions of DUL (10 µg/ml) for alkali degradation studies were 
prepared using 0.1 M sodium hydroxide in methanol, and the resultant solutions were 
stand for 24 hr. 
(d) Dry heat: For dry heat degradation studies drug powder was exposed in an oven 
(80 °C) for 2 days. The solids were allowed to cool. DUL was accurately weighed and 
transferred to a volumetric flask containing few ml of methanol. The volume was made up 
to the mark with methanol. The solution was further diluted with methanol to obtain final 
concentration of 10 µg/ml of DUL. 
(e) Photolytic degradation: For photolytic degradation study drug powder was exposed to 
direct sunlight for 24 hr. After exposure, solid was accurately weighed and transferred to 
volumetric flask containing few ml of methanol. The volume was made up to the mark with 
methanol. The solution was further diluted with methanol to obtain final concentration of 10 
µg/ml of DUL (ICH, Q1B, 1996).   Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine …  867 
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